21 August 2020 : Clinical Research
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade
Jingjing Chen12ACE, Shao Liu1ADE, Hui Xu23AF*, Wei Wang3BC, Yanyun Xie3B, Wenbin Tang3B, Qiongjing Yuan3B, Li Zheng4D, Lizhen Lin35F, Shuangshuang Fu6F, Jinmei Shen7CDOI: 10.12659/MSM.922839
Med Sci Monit 2020; 26:e922839
Supplementary Table 1 Baseline characteristics of the matched IgAN patients only with hematuria initially (n=103).
| Characteristics at biopsy | Treatment group (n=37) | Untreated group (n=66) | P |
|---|---|---|---|
| Clinical characteristics | |||
| Male (%) | 10 (27.0) | 17 (25.8) | 0.89 |
| Age (years) | 31±12 | 29±10 | 0.29 |
| Serum creatinine (μmol/L) | 72.0 (59.0–86.5) | 71.0 (58.8–77.5) | 0.26 |
| Initial eGFR (ml/min/1.73 m) | 102.2±23.7 | 107.9±25.2 | 0.26 |
| Hematuria, (cells/hpf) | 37.0 (27.0–71.0) | 33.0 (13.0–68.0) | 0.14 |
| Systolic pressure (mmHg) | 120 (108–128) | 118 (104–124) | 0.53 |
| Diastolic pressure (mmHg) | 76 (70–84) | 71 (65–80) | 0.18 |
| Hypertension, n (%) | 5 (13.5) | 5 (7.6) | 0.49 |
| Hemoglobin (g/L) | 127 (116–131) | 127 (117–134) | 0.69 |
| Albumin (g/L) | 42.1±4.6 | 42.1±4.4 | 0.96 |
| Uric acid (μmol/L) | 288 (227–339) | 283 (255–309) | 0.67 |
| Low hemoglobin, n (%) | 4 (10.8) | 8 (12.1) | 1.00 |
| Hypoalbuminemia, n (%) | 2 (5.4) | 3 (4.5) | 1.00 |
| Hyperuricemia, n (%) | 4 (10.8) | 7 (10.6) | 1.00 |
| Biopsy characteristics | |||
| M1, n (%) | 21 (56.8) | 30 (45.5) | 0.27 |
| E1, n (%) | 7 (18.9) | 16 (24.2) | 0.53 |
| S1, n (%) | 15 (40.5) | 20 (30.3) | 0.29 |
| T1–2, n (%) | 1 (2.7) | 5 (7.6) | 0.42 |
| C1–2, (%)* | 3 (8.1) | 4 (6.1) | 0.70 |
| Duration from initial diagnosis to start of therapy (months) | 5.0 (1.0–21.0) | 5.6 (1.0–12.0) | 0.94 |
| * Crescents >50% were excluded. eGFR – estimated glomerular filtration rate; RASB – reninangiotensin system blockers; M – mesangial hypercellularity; E–endocapillary hypercellularity; S – segmental glomerulosclerosis; T – tubular atrophy/interstitial fibrosis; C – crescent. | |||